232 related articles for article (PubMed ID: 8208532)
1. Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells.
Pim D; Storey A; Thomas M; Massimi P; Banks L
Oncogene; 1994 Jul; 9(7):1869-76. PubMed ID: 8208532
[TBL] [Abstract][Full Text] [Related]
2. The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain.
Mansur CP; Marcus B; Dalal S; Androphy EJ
Oncogene; 1995 Feb; 10(3):457-65. PubMed ID: 7845670
[TBL] [Abstract][Full Text] [Related]
3. Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro.
Nakagawa S; Watanabe S; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
Virology; 1995 Oct; 212(2):535-42. PubMed ID: 7571423
[TBL] [Abstract][Full Text] [Related]
4. Cellular targets of the oncoproteins encoded by the cancer associated human papillomaviruses.
Howley PM; Münger K; Romanczuk H; Scheffner M; Huibregtse JM
Princess Takamatsu Symp; 1991; 22():239-48. PubMed ID: 1668886
[TBL] [Abstract][Full Text] [Related]
5. HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6.
Pim D; Banks L
Oncogene; 1999 Dec; 18(52):7403-8. PubMed ID: 10602499
[TBL] [Abstract][Full Text] [Related]
6. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth.
Pim D; Massimi P; Banks L
Oncogene; 1997 Jul; 15(3):257-64. PubMed ID: 9233760
[TBL] [Abstract][Full Text] [Related]
7. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner.
López-Ocejo O; Viloria-Petit A; Bequet-Romero M; Mukhopadhyay D; Rak J; Kerbel RS
Oncogene; 2000 Sep; 19(40):4611-20. PubMed ID: 11030150
[TBL] [Abstract][Full Text] [Related]
8. Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation.
Thomas M; Matlashewski G; Pim D; Banks L
Oncogene; 1996 Jul; 13(2):265-73. PubMed ID: 8710365
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of serum- and calcium-induced terminal differentiation of human keratinocytes by HPV 16 E6: study of the association with p53 degradation, inhibition of p53 transactivation, and binding to E6BP.
Sherman L; Itzhaki H; Jackman A; Chen JJ; Koval D; Schlegel R
Virology; 2002 Jan; 292(2):309-20. PubMed ID: 11878933
[TBL] [Abstract][Full Text] [Related]
10. HPV-18 E6 mediated inhibition of p53 DNA binding activity is independent of E6 induced degradation.
Thomas M; Massimi P; Jenkins J; Banks L
Oncogene; 1995 Jan; 10(2):261-8. PubMed ID: 7838526
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of transformation by the human papillomaviruses.
Howley PM; Münger K; Werness BA; Phelps WC; Schlegel R
Princess Takamatsu Symp; 1989; 20():199-206. PubMed ID: 2562182
[TBL] [Abstract][Full Text] [Related]
12. Dispensability of p53 degradation for tumorigenicity and decreased serum requirement of human papillomavirus type 16 E6.
Inoue T; Oka K; Yong-Il H; Vousden KH; Kyo S; Jing P; Hakura A; Yutsudo M
Mol Carcinog; 1998 Mar; 21(3):215-22. PubMed ID: 9537653
[TBL] [Abstract][Full Text] [Related]
13. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products.
Münger K; Scheffner M; Huibregtse JM; Howley PM
Cancer Surv; 1992; 12():197-217. PubMed ID: 1322242
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of HPV E6 proteins in cellular transformation.
Huibregtse JM; Beaudenon SL
Semin Cancer Biol; 1996 Dec; 7(6):317-26. PubMed ID: 9284524
[TBL] [Abstract][Full Text] [Related]
15. Modulation of transcriptional regulatory properties of p53 by HPV E6.
Crook T; Fisher C; Masterson PJ; Vousden KH
Oncogene; 1994 Apr; 9(4):1225-30. PubMed ID: 8134125
[TBL] [Abstract][Full Text] [Related]
16. Repression of p53 transcriptional activity by the HPV E7 proteins.
Massimi P; Banks L
Virology; 1997 Jan; 227(1):255-9. PubMed ID: 9007083
[TBL] [Abstract][Full Text] [Related]
17. p53-independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene.
Spitkovsky D; Aengeneyndt F; Braspenning J; von Knebel Doeberitz M
Oncogene; 1996 Sep; 13(5):1027-35. PubMed ID: 8806692
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus E6 and E7: proteins which deregulate the cell cycle.
Tommasino M; Crawford L
Bioessays; 1995 Jun; 17(6):509-18. PubMed ID: 7575492
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification.
Hiller T; Poppelreuther S; Stubenrauch F; Iftner T
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1262-7. PubMed ID: 16835321
[TBL] [Abstract][Full Text] [Related]
20. Functional consequences of directed mutations in human papillomavirus E6 proteins: abrogation of p53-mediated cell cycle arrest correlates with p53 binding and degradation in vitro.
Slebos RJ; Kessis TD; Chen AW; Han SM; Hedrick L; Cho KR
Virology; 1995 Apr; 208(1):111-20. PubMed ID: 11831691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
